Kamada Ltd. – NASDAQ:KMDA

Add to watchlist

$7.21

+1.29

+21.79%

Market closed

Open in 21 minutes

-4.67%

month

-4.67%

quarter

-4.82%

year

Market Cap	344.86M
Enterprise value	208.98M

P/E	-92
EV/Sales	1.61
EV/EBITDA	19.33
Price/Sales	1.72
Price/Book	1.26
PEG ratio	22.54
EPS	0.24

Revenue	151.12M
EBITDA	25.36M
Income	12.45M
Revenue Q/Q	21.77%
Revenue Y/Y	14.52%

Profit margin	-1.79%
Oper. margin	3.5%
Gross margin	36.11%
EBIT margin	3.5%
EBITDA margin	16.78%

Get more financial ratios!

Every financial ratio you might need
10 years history
Forward ratios (Analysts estimates)

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Kamada Ltd. Stock Forecast

M Q Y

Last Year

$20

Potential upside: 177.39%

Analysts Price target
Financials & Ratios estimates

Kamada Ltd. (NASDAQ:KMDA): Profit margin
Jun 2023	37.44M	1.81M	4.84%
Sep 2023	37.93M	3.22M	8.5%
Dec 2023	38.35M	5.05M	13.19%
Mar 2024	37.39M	2.36M	6.32%

Kamada Ltd. (NASDAQ:KMDA): Debt to assets
Jun 2023	314389000	137.63M	43.78%
Sep 2023	337056000	98.66M	29.27%
Dec 2023	351969743	109.96M	31.24%
Mar 2024	340058302	95.78M	28.17%

Kamada Ltd. (NASDAQ:KMDA): Cash Flow
Jun 2023	1.81M	-1.04M	-5.85M
Sep 2023	921K	-1.72M	31.29M
Dec 2023	4.47M	-2.07M	512.21K
Mar 2024	1.01M	-2.65M	-5.68M

Kamada Ltd. alternative data

Social Media

🎓 Academy: How impactful can social media data be in investment decisions

Kamada Ltd. (NASDAQ:KMDA): Employee count
Aug 2023	380
Sep 2023	380
Oct 2023	380
Nov 2023	380
Dec 2023	380
Jan 2024	380
Feb 2024	380
Mar 2024	378
Apr 2024	378
May 2024	378
Jun 2024	378
Jul 2024	378

Kamada Ltd.
Hedge Funds Holdings Q1 2023

10.77% -1.99%

of KMDA is owned by hedge funds

16 -12

hedge funds hold KMDA stock

4.82M -899.79K

shares is hold by hedge funds

KMDA hedge funds holdings changes

Status	Patent	Filling date	Issue date
Grant	Grant Utility: Methods and uses of alpha 1-antitrypsin for early intervention in pulmonary diseases Filling date: 21 Feb 2018 Issue date: 30 Mar 2021	21 Feb 2018	30 Mar 2021
Application	Application METHODS AND COMPOSITIONS FOR PRE-EMPTIVE TREATMENT OF GRAFT VERSUS HOST DISEASE Filling date: 2 Dec 2020 Issue date: 25 Mar 2021	2 Dec 2020	25 Mar 2021
Application	Application DRY POWDER FORMULATIONS OF ALPHA-1 ANTITRYPSIN Filling date: 20 Dec 2017 Issue date: 25 Mar 2021	20 Dec 2017	25 Mar 2021
Application	Application METHODS OF INDUCING IMMUNE TOLERANCE AND REDUCING ANTI-DRUG ANTIBODY RESPONSE Filling date: 10 Dec 2018 Issue date: 14 Jan 2021	10 Dec 2018	14 Jan 2021
Application	Application METHODS AND COMPOSITIONS FOR PRE-EMPTIVE TREATMENT OF GRAFT VERSUS HOST DISEASE Filling date: 1 Jul 2020 Issue date: 22 Oct 2020	1 Jul 2020	22 Oct 2020
Application	Application METHODS AND COMPOSITIONS FOR REDUCING LUNG INJURY ASSOCIATED WITH LUNG TRANSPLANTATION Filling date: 29 Oct 2018 Issue date: 10 Sep 2020	29 Oct 2018	10 Sep 2020
Grant	Grant Utility: Compositions derived from Cohn fraction paste and use thereof Filling date: 11 Aug 2016 Issue date: 28 Jul 2020	11 Aug 2016	28 Jul 2020
Grant	Grant Utility: Therapy and prophylaxis of infectious disease caused by zika virus Filling date: 31 Aug 2018 Issue date: 23 Jun 2020	31 Aug 2018	23 Jun 2020
Application	Application IMMUNOGLOBULIN COMPOSITIONS AND PROCESS FOR OBTAINING THE SAME Filling date: 12 Jun 2018 Issue date: 21 May 2020	12 Jun 2018	21 May 2020
Application	Application MULTIPLE-VARIABLE DOSE REGIMEN FOR TREATING DIABETES Filling date: 10 Oct 2017 Issue date: 13 Feb 2020	10 Oct 2017	13 Feb 2020

Kamada Ltd.
Earnings Call Transcripts

Quarter	Transcript
Q1 2024 8 May 2024	Q1 2024 Earnings Call Transcript
Q4 2023 6 Mar 2024	Q4 2023 Earnings Call Transcript
Q3 2023 13 Nov 2023	Q3 2023 Earnings Call Transcript
Q2 2023 16 Aug 2023	Q2 2023 Earnings Call Transcript

KMDA earnings call transcripts

Kamada Ltd.
Executives

Insider	Age	Compensation
Mr. Amir London (1969) Chief Executive Officer	56	$628,000
Mr. Chaime Orlev (1970) Chief Financial Officer	55	$332,000
Mr. Eran Nir (1973) Vice President of Operations	52	$328,000
Dr. Michal Ayalon-Soffer (1967) Vice President of R&D and IP	58	$283,000

Kamada Ltd.
Latest News

Wednesday, 13 November 2024
09:54	Kamada Ltd. (KMDA) Q3 2024 Earnings Call Transcript	seekingalpha.com
Monday, 23 September 2024
07:00	Kamada Announces Expansion of Plasma Collection Operations in Texas with the Opening of New Site in Houston	globenewswire.com
Wednesday, 14 August 2024
13:45	Kamada Ltd. (KMDA) Q2 2024 Earnings Call Transcript	seekingalpha.com
Wednesday, 7 August 2024
07:00	Kamada to Announce Second Quarter and First Half Ended June 30, 2024 Financial Results and Host Conference Call on August 14, 2024	globenewswire.com
Monday, 29 July 2024
15:04	3 Promising Biotech Stocks You Can Pick Up for Less Than $10	investorplace.com
Wednesday, 8 May 2024
11:55	Kamada Ltd. (KMDA) Q1 2024 Earnings Call Transcript	seekingalpha.com
07:00	Kamada Reports Strong First Quarter 2024 Financial Results with Year-Over-Year Top-Line Growth of 23% and a 96% Increase in Profitability; Raises Full-Year Financial Guidance	globenewswire.com
Wednesday, 1 May 2024
07:00	Kamada to Announce First Quarter 2024 Financial Results and Host Conference Call on May 8, 2024	globenewswire.com
Wednesday, 6 March 2024
14:22	Kamada Ltd. (KMDA) Q4 2023 Earnings Call Transcript	Seeking Alpha
Wednesday, 28 February 2024
07:00	Kamada to Announce Fourth Quarter and Fiscal Year 2023 Financial Results, and Provide 2024 Financial Guidance on March 6, 2024	GlobeNewsWire
Friday, 8 December 2023
18:42	Kamada: Kedrion Deal Locks In Growth	Seeking Alpha
Wednesday, 8 November 2023
07:00	Kamada to Announce Third Quarter and First Nine Months Ended September 30, 2023 Financial Results and Host Conference Call on November 13, 2023	GlobeNewsWire
Monday, 9 October 2023
08:53	These Israeli pharmaceutical stocks are down in the wake of Hamas attack	Market Watch
Wednesday, 9 August 2023
07:00	Kamada to Announce Second Quarter and First Half Ended June 30, 2023 Financial Results and Host Conference Call on August 16, 2023	GlobeNewsWire
Wednesday, 21 June 2023
05:10	Kamada: Deep Dive Following FIMI Placement, Rate Buy	Seeking Alpha
Wednesday, 24 May 2023
13:21	Kamada Ltd. (KMDA) Q1 2023 Earnings Call Transcript	Seeking Alpha
Wednesday, 17 May 2023
07:00	Kamada to Announce First Quarter 2023 Financial Results and Host Conference Call on May 24, 2023	GlobeNewsWire
Wednesday, 15 March 2023
16:07	Kamada Ltd. (KMDA) Q4 2022 Earnings Call Transcript	Seeking Alpha
Monday, 28 November 2022
09:02	New Strong Buy Stocks for November 28th	Zacks Investment Research
Tuesday, 22 November 2022
10:35	Kamada Ltd. (KMDA) Q3 2022 Earnings Call Transcript	Seeking Alpha
09:47	Kamada (KMDA) Q3 Earnings and Revenues Top Estimates	Zacks Investment Research
Wednesday, 17 August 2022
13:58	Kamada Ltd. (KMDA) CEO Amir London on Q2 2022 Results - Earnings Call Transcript	Seeking Alpha
09:47	Kamada (KMDA) Q2 Earnings Beat Estimates	Zacks Investment Research
Wednesday, 10 August 2022
07:00	Kamada to Announce Second Quarter and First Half Ended June 30, 2022 Financial Results and Host Conference Call on August 17, 2022	GlobeNewsWire
Tuesday, 17 May 2022
11:06	Kamada Ltd. (KMDA) CEO Amir London on Q1 2022 Results - Earnings Call Transcript	Seeking Alpha
09:47	Kamada (KMDA) Reports Q1 Loss, Lags Revenue Estimates	Zacks Investment Research
Wednesday, 11 May 2022
07:00	Kamada to Announce First Quarter Ended March 31, 2022 Financial Results and Host Conference Call on May 17, 2022	GlobeNewsWire
Tuesday, 15 March 2022
09:48	Kamada Ltd.'s (KMDA) CEO Amir London on Q4 2021 Results - Earnings Call Transcript	Seeking Alpha
Monday, 22 November 2021
12:07	Kamada Ltd. (KMDA) CEO Amir London on Q3 2021 Results - Earnings Call Transcript	Seeking Alpha
10:44	Kamada Stock Jumps After Acquisition Of Four Plasma-Derived Products	Benzinga

Ideas & Opinions

Seeking Alpha 8 Dec 2023

Kamada: Kedrion Deal Locks In Growth
Seeking Alpha 5 Dec 2023

Celebrating Seeking Alpha's New Analysts - November 2023 Edition
Seeking Alpha 21 Nov 2023

Kamada: Solid Specialty Plasma Play
Seeking Alpha 21 Jun 2023

Kamada: Deep Dive Following FIMI Placement, Rate Buy
Seeking Alpha 1 Apr 2021

Checking Back In On Kamada

Frequently Asked Questions (FAQ)

What's the price of Kamada Ltd. stock today?

One share of Kamada Ltd. stock can currently be purchased for approximately $7.21.
When is Kamada Ltd.'s next earnings date?

Unfortunately, Kamada Ltd.'s (KMDA) next earnings date is currently unknown.
Does Kamada Ltd. pay dividends?

No, Kamada Ltd. does not pay dividends.
How much money does Kamada Ltd. make?

Kamada Ltd. has a market capitalization of 344.86M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 10.19% to 142.52M US dollars.
What is Kamada Ltd.'s stock symbol?

Kamada Ltd. is traded on the NASDAQ under the ticker symbol "KMDA".
What is Kamada Ltd.'s primary industry?

Company operates in the Healthcare sector and Drug Manufacturers - Specialty & Generic industry.
How do i buy shares of Kamada Ltd.?

Shares of Kamada Ltd. can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Who are Kamada Ltd.'s key executives?
Kamada Ltd.'s management team includes the following people:
- Mr. Amir London Chief Executive Officer(age: 56, pay: $628,000)
- Mr. Chaime Orlev Chief Financial Officer(age: 55, pay: $332,000)
- Mr. Eran Nir Vice President of Operations(age: 52, pay: $328,000)
- Dr. Michal Ayalon-Soffer Vice President of R&D and IP(age: 58, pay: $283,000)
How many employees does Kamada Ltd. have?

As Jul 2024, Kamada Ltd. employs 378 workers.
When Kamada Ltd. went public?

Kamada Ltd. is publicly traded company for more then 12 years since IPO on 31 May 2013.
What is Kamada Ltd.'s official website?

The official website for Kamada Ltd. is kamada.com.
How can i contact Kamada Ltd.?

Kamada Ltd. can be reached via phone at +972 8 940 6472.
What is Kamada Ltd. stock forecast & price target?

Based on 1 Wall Street analysts` predicted price targets for Kamada Ltd. in the last 12 months, the avarage price target is $20. The average price target represents a 177.39% change from the last price of $7.21.

Kamada Ltd.

kamada.com

Exchange:

NASDAQ

Full time employees:

378

Industry:

Drug Manufacturers - Specialty & Generic

Sector:

Healthcare

Kamada Ltd. provides plasma-derived protein therapeutics. It operates in two segments, Proprietary Products and Distribution. The company offers KAMRAB/KEDRAB for prophylaxis of rabies disease; CYTOGAM for prophylaxis of cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplant; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; VARIZIG for post exposure prophylaxis of varicella; and GLASSIA for intravenous AATD. It also provides KamRho (D) IM for prophylaxis of hemolytic disease of newborns; KamRho (D) IV for immune thermobocytopunic purpura; and snake bite antiserum to treat snake bites by the vipera palaestinae and echis coloratus. In addition, the company distributes BRAMITOB to manage chronic pulmonary infection; FOSTER to treat asthma; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; AEROBIKA, an OPEP device; RUPAFIN for Allergic rhinitis and Urticaria; IVIG for immunodeficiency-related conditions; VARITECT for chicken pox and zoster herpes; ZUTECTRA and HEPATECT CP for hepatitis B; MEGALOTECT CP for cytomegalovirus virus; RUCONEST for angioedema attacks; heparin sodium injection for thrombo-embolic disorders and prophylaxis of deep vein thrombosis and thromboembolic events; ALBUMIN for blood plasma; Factor VIII for hemophilia type A; and Factor IX for hemophilia type B. Further, it offers IXIARO for Japanese encephalitis; VIVOTIF for Salmonella Typhi; PROCYSBI for nephropathic cystinosis; LAMZEDE for alpha-mannosidosis ; and ELIGARD for prostate cancer. The company markets its products through strategic partners in the United States, as well as through distributors internationally. Kamada Ltd. has strategic partnerships with Takeda Pharmaceuticals Company Limited; PARI GmbH; and Kedrion Biopharma. The company was incorporated in 1990 and is headquartered in Rehovot, Israel.

+972 8 940 6472

2 Holzman Street
Rehovot, 7670402

CIK: 0001567529
ISIN: IL0010941198
CUSIP: M6240T109